Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study:Differentiating between Baseline ‘Predictors’ and Longitudinal ‘Targets’ by Cattaneo, Annamaria et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/npp.2012.191
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., ... Pariante, C. M. (2013).
Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study:
Differentiating between Baseline ‘Predictors’ and Longitudinal ‘Targets’. Neuropsychopharmacology, 38(3), 377-
385. 10.1038/npp.2012.191
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Candidate Genes Expression Profile Associated with
Antidepressants Response in the GENDEP Study: Differentiating
between Baseline ‘Predictors’ and Longitudinal ‘Targets’
Annamaria Cattaneo1, Massimo Gennarelli1,2, Rudolf Uher3, Gerome Breen3, Anne Farmer3,
Katherine J Aitchison3,4, Ian W Craig3, Christoph Anacker5, Patricia A Zunsztain5, Peter McGuffin3 and
Carmine M Pariante*,5
1Department of Biomedical Sciences and Biotechnology, Genetic and Biology Section, University of Brescia, Brescia, Italy; 2Genetic Unit, IRCCS
San Giovanni di Dio, Fatebenefratelli Centre, Brescia, Italy; 3Institute of Psychiatry, MRC Social, Genetic and Developmental Psychiatry, King’s
College London, London, UK; 4Department of Psychiatry, University of Alberta, Edmonton, Canada; 5Department of Psychological Medicine,
Institute of Psychiatry, Section of Perinatal Psychiatry and Stress, Psychiatry and Immunology (SPI-lab), King’s College London, London, UK
To improve the ‘personalized-medicine’ approach to the treatment of depression, we need to identify biomarkers that, assessed before
starting treatment, predict future response to antidepressants (‘predictors’), as well as biomarkers that are targeted by antidepressants
and change longitudinally during the treatment (‘targets’). In this study, we tested the leukocyte mRNA expression levels of genes
belonging to glucocorticoid receptor (GR) function (FKBP-4, FKBP-5, and GR), inflammation (interleukin (IL)-1a, IL-1b, IL-4, IL-6, IL-7, IL-8,
IL-10, macrophage inhibiting factor (MIF), and tumor necrosis factor (TNF)-a), and neuroplasticity (brain-derived neurotrophic factor (BDNF),
p11 and VGF), in healthy controls (n¼ 34) and depressed patients (n¼ 74), before and after 8 weeks of treatment with escitalopram or
nortriptyline, as part of the Genome-based Therapeutic Drugs for Depression study. Non-responders had higher baseline mRNA levels
of IL-1b (þ 33%), MIF (þ 48%), and TNF-a (þ 39%). Antidepressants reduced the levels of IL-1b ( 6%) and MIF ( 24%), and
increased the levels of GR (þ 5%) and p11 (þ 8%), but these changes were not associated with treatment response. In contrast,
successful antidepressant response was associated with a reduction in the levels of IL-6 ( 9%) and of FKBP5 ( 11%), and with an
increase in the levels of BDNF (þ 48%) and VGF (þ 20%)—that is, response was associated with changes in genes that did not predict, at
the baseline, the response. Our findings indicate a dissociation between ‘predictors’ and ‘targets’ of antidepressant responders. Indeed,
while higher levels of proinflammatory cytokines predict lack of future response to antidepressants, changes in inflammation associated
with antidepressant response are not reflected by all cytokines at the same time. In contrast, modulation of the GR complex and of
neuroplasticity is needed to observe a therapeutic antidepressant effect.
Neuropsychopharmacology (2013) 38, 377–385; doi:10.1038/npp.2012.191; published online 19 September 2012
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INTRODUCTION
Antidepressants are commonly prescribed drugs, but the
treatment protocols are dictated by clinical practice and
personal preferences rather than by a ‘biomarker-based’
personalized medicine approach (Uher, 2011). These drugs
are used in patients with major depression, one of the most
common psychiatric disorders and a leading cause of
disability worldwide (Gustavsson et al, 2011). However,
despite the increasing variety of antidepressants currently
available, only a third of patients respond adequately to
treatment, and up to half of them relapse within 1 year
(Thase, 2006). Unfortunately, we still cannot predict the
likelihood of response of an individual patient to a specific
drug (Uher, 2011). Therefore, there is a pressing need to
identify biomarkers that, assessed before starting treatment,
‘predict’ future response, as well as biomarkers that are
‘targeted’ by antidepressants and change longitudinally
during antidepressant treatment. In addition to fostering
personalized medicine, establishing ‘predictors’ and ‘target’
biomarkers could lead to the identification of novel
pathophysiological pathways relevant to depression, and
thus novel mechanisms for designing therapeutic strategies.
Based on the current conceptualization of depression, we
suggest that hypothesis-driven, blood-based biomarker
analysis should focus on the biological systems that
have been more consistently described as abnormal in
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depression: the glucocorticoid receptor (GR) complex,
inflammation, and neuroplasticity (Chopra et al, 2011).
One of the most consistent biological findings in depres-
sion is a hyperactivity of the hypothalamic–pituitary–
adrenal (HPA) axis (Pariante and Lightman, 2008), as
shown by a multitude of studies describing high levels of
cortisol, the main HPA axis hormone, in the context of
reduced function of the GR, the cortisol receptor primarily
involved in HPA axis regulation during stress. This reduced
GR function, or glucocorticoid resistance, is particularly
evident in patients with treatment-resistant depression
(Bauer et al, 2003; Juruena et al, 2009), and indeed
persistent glucocorticoid resistance during antidepressant
treatment is associated with early relapse (Ising et al, 2007;
Ribeiro et al, 1993). Moreover, polymorphisms in the GR
(or NR3C1) gene, and in the gene for the GR-associated,
FKBP-5 co-chaperone protein, have been shown to regulate
GR function and to predict antidepressant treatment response
(Binder, 2009; Spijker and van Rossum, 2012; Uher et al,
2009). Therefore, the expression levels of GR-related genes
are important candidate biomarkers in relation with
antidepressant response.
A second biological system potentially involved in
antidepressant response is inflammation. Pro-inflammatory
cytokines, and in particular interleukin (IL)-1b, IL-6, and
tumor necrosis factor (TNF)-a, are increased in depressed
patients as compared with controls (Dowlati et al, 2010); in
turn, antidepressants have been shown to have anti-
inflammatory effects (Hannestad et al, 2011), and anti-
inflammatory drugs, such as celecoxib and TNF-a antago-
nists, have been shown to have antidepressant properties or
to improve antidepressant response (Haroon et al, 2012).
Interestingly in this context, higher levels of inflammation
seem to identify depressed patients who are less likely to
respond to antidepressant treatment (Benedetti et al, 2002;
Lanquillon et al, 2000; Sluzewska et al, 1997). In addition,
polymorphisms in immune genes, such as in IL-1b, IL-11,
and TNF-a, have been associated with reduced responsive-
ness to antidepressant therapy (Uher et al, 2010; Wong et al,
2008; Yu et al, 2003). Consistent with this notion, the
elevated levels of IL-1b, IL-6, and TNF-a tend to diminish in
parallel with antidepressant response (Janssen et al, 2010;
Yoshimura et al, 2009). Of note is also the proposed model
that the above-mentioned glucocorticoid resistance results
from the direct molecular action of the activated inflam-
matory pathways on the GR complex, and that, in turn, the
glucocorticoid resistance maintains the inflammatory status
by reducing the inhibitory control of endogenous gluco-
corticoids on the immune system (Zunszain et al, 2011).
This model suggests a common pathogenic process under-
lying both the HPA axis and the inflammatory abnormal-
ities in depression, and thus identifies expression levels of
inflammatory genes as further important candidate bio-
markers in relation with antidepressant response.
Finally, one of the potential mechanisms by which
excessive HPA axis activity and inflammatory responses
may contribute to the pathogenesis of depression is through
inhibition of neurotrophic factors and disturbance of
neuroplasticity (Lee and Kim, 2010). The neurotrophin,
brain-derived neurotrophic factor (BDNF), is the most
studied molecule within the neuroplasticity network, and we
and others have shown that BDNF levels are reduced in the
serum and in the leukocytes mRNA of depressed patients,
and that, in turn, pharmacological and non-pharmacologi-
cal antidepressant therapies increase BDNF to levels similar
to those in healthy controls (Bocchio-Chiavetto et al, 2010;
Cattaneo et al, 2010a, b; Pandey et al, 2010). The expression
levels of BDNF- and neuroplasticity-related genes are
therefore another class of important candidate biomarkers
in relation with antidepressant response.
In this study, to capture a comprehensive picture of the
biological and clinical interaction between these three bio-
logical systems in relationship with antidepressant treat-
ment, we examined the gene expression (blood mRNA via
PaxGene tubes) of 15 genes belonging to the GR (three genes),
inflammation (nine genes), and neuroplasticity (three
genes) pathways. We studied a well-characterized group of
depressed patients from the Genome-based Therapeutic
Drugs for Depression (GENDEP) study (Uher et al, 2009,
2010), before and after 8 weeks of treatment with one of two
pharmacologically different antidepressants: the selective
serotonin reuptake inhibitor, escitalopram, and the tricyclic
noradrenaline reuptake inhibitor, nortryptline (and in a
group of matched controls). We selected all patients (n¼ 74)
who were drug-free for at least 2 weeks before enrolling into
the trial, and had provided PaxGene tubes at both baseline
and follow-up (after 8 weeks of antidepressants). We mea-
sured the transcriptional levels of the following genes:
for the GR complex, FKBP-4, FKBP-5, and GR; for the
inflammatory system, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8,
IL-10, macrophage inhibiting factor (MIF), and TNF-a; and
for neuroplasticity, BDNF, p11, and VGF (non-acronymic).
We wished to answer three questions: first, which genes at
baseline (ie, before starting antidepressant treatment)
differentiate depressed patients vs controls; second, which
genes, again at baseline, predict treatment response to
subsequent antidepressant treatment (‘predictors’); and
third, which genes, assessed prospectively (ie, at baseline
and after 8 weeks of antidepressant treatment) change in
parallel with treatment response (‘targets’).
MATERIALS AND METHODS
Study Design
The GENDEP project is an open-label part-randomized
multicentre pharmacogenetic study with two active phar-
macological treatment arms (Keers et al, 2010; Uher et al,
2009, 2010). It was designed to establish clinical and genetic
determinants of therapeutic response to two antidepres-
sants with different primary modes of action: nortriptyline
and escitalopram. The overall study has been extensively
described before (see Supplementary Material for details).
In total, 9 psychiatric centers in 8 European countries
recruited 811 adult outpatients (296 men and 514 women),
aged between 19 and 72 (mean age 42.5, SD¼ 11.8) suffering
from unipolar depression of at least moderate severity
according to International Classification of Diseases 10/
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition, and established by the semi-structured
SCAN interview.
Severity of depressive symptoms and treatment response
was assessed by weekly administration of three established
measures of depression severity: the clinician-rated 10-item
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Montgomery–Asberg Depression Rating Scale (MADRS;
Montgomery and Asberg, 1979), the 17-item Hamilton
Rating Scale for Depression (HRSD–17; Hamilton, 1967),
and the Beck Depression Inventory (BDI; Beck et al, 1961).
The average participant in the original sample was in his/
her second episode of depression and scored 28.7 (SD¼ 6.7)
on the MADRS, 21.8 (SD¼ 5.3) on the 17-item HDRS, and
28.2 (SD¼ 9.7) on the BDI.
A psychometric analysis has found that the MADRS was
the most internally consistent and informative of the three
scales (Uher et al, 2008), and therefore in the pharmaco-
genetic analyses already published (Uher et al, 2010), and
in the current gene expression study, we have used the
MADRS score as a primary outcome measure of ‘treatment
response’. Response to antidepressant medication was
quantified as percentage reduction in the MADRS score
from baseline to week 12, and responders were identified as
patients with a reduction in MADRS450%.
Subjects
For this study, we selected all patients who had been drug-
free for at least 2 weeks before entering into the trial and
provided a baseline and a follow-up PaxGene tube (n¼ 74).
Their average (SD) age was 38.3±10.9 and, there were 31
males and 43 females. The average participant in our study
was in his/her second episode of moderately severe
depression and scored, at baseline, 28.7 (SD¼ 4.2) on the
MADRS, 20.7 (SD¼ 4.1) on the HRSD–17, and 27.5
(SD¼ 10.2) on the BDI. There were no significant differ-
ences between patients treated with escitalopram (n¼ 38) or
nortryptiline (n¼ 36), in age (38±12.4 vs 36±9.4, p¼ 0.25),
gender (F/M was 20/18 vs 23/13, p¼ 0.2), and in the
response rate (responders/non-responders was 26/12 vs 25/
11, p¼ 0.6).
Controls were recruited in London (UK), through adver-
tisement in local newspapers, hospitals, and job centers, as
well as from existing volunteer databases. Controls were
screened using the Psychosis Screening Questionnaire
(Bebbington and Nayani, 1995), and were excluded if they
met criteria for a present or past psychotic disorder, or if
taking any kind of hormonal treatment; their average age
was 35.2 (SD¼ 8), and there were 19 males and 15 females.
There were no significant differences in age and gender
between patients and controls (p¼ 0.14 for age, and p¼ 0.13
for gender distribution).
Gene Expression Analyses
We measured the leukocytes mRNA levels of the above-
mentioned candidate genes involved in GR function (FKBP-
4, FKBP-5, and GR), inflammatory system (IL1-a, IL-1b, IL-
4, IL-6, IL-7, IL-8, IL-10, MIF, and TNF-a), and neuroplas-
ticity (BDNF, p11, and VGF). Each sample was assayed in
duplicate, and each target gene was normalized to the
expression of three reference genes, glyceraldehyde
3-phosphate dehydrogenase, beta-actin, and beta-2-micro-
globulin. The expression levels of each target gene were
normalized to the geometric mean of all three reference
genes, and the Pfaffl method was used to determine relative
target gene expression of each gene in patients as compared
with controls (see Supplementary Material for details).
Data Analyses
Data were analyzed using the Statistical Package for Social
Sciences, version 17.0 (SPSS). Continuous variables are
presented as mean±SD or SEM, as indicated. Categorical
variables were tested by means of w2 and Fisher’s tests.
Univariate analysis of variance was used for comparing the
mean values of the mRNA levels of the genes of interest, at
baseline, in patients vs controls and in responders vs non-
responders. Changes over time were analyzed using the
repeated-measures General Linear Model with time (T0 and
T8) and response (yes/no) as factors. The Greenhouse–
Geisser correction was applied to degrees of freedom when
the sphericity assumption was violated. Parametric correla-
tion analyses using Pearson’s coefficient were used to test
the association between genes and the improvement in the
depressive symptoms measured as changes in the MADRS
score. Linear regression analyses were used to test for
predictors of the treatment outcome.
RESULTS
Biomarkers Differences between Patients at Baseline,
and Controls
Patients (at baseline) and controls differed in the expression
of most of the examined genes (Table 1). Specifically, we
found that depressed patients, as compared with controls,
had higher FKBP-5 mRNA levels (þ 27%, F¼ 69.4,
po0.0001) and lower GR mRNA levels ( 18%, F¼ 63.2,
po0.0001). Moreover, they had higher mRNA levels of
IL-1b, (þ 48%, F¼ 117.9, po0.0001), IL-6 (þ 24%, F¼ 86.3,
po0.0001), MIF (þ 32%, F¼ 34.8, po0.0001), and TNF-a
(þ 58%, F¼ 87.7, po0.0001), and lower levels of IL-4
( 9%, F¼ 5.6, p¼ 0.02). Finally, depressed patients had
lower mRNA levels of BDNF ( 24%, F¼ 46.5, po0.0001),
p11 ( 16%, F¼ 12.1, p¼ 0.001), and VGF ( 36%, F¼ 37.3,
po0.0001).
Baseline Differences in Biomarkers between Responders
and Non-Responders (‘Predictors’)
As mentioned above, treatment response was defined as a
percentage reduction 450% in the MADRS score from
baseline to week 12. In this sample, we had 51 responders
and 23 non-responders: 26 responders to escitalopram, 12
non-responders to escitalopram, 25 responders to nortrypt-
line, and 11 non-responders to nortryptline. There were no
differences in age (38.3±1.6 vs 38.4±2.2 years, Fo0.1,
p¼ 0.98), gender distribution (F/M¼ 31/20 vs 12/11, w2¼ 0.5,
p¼ 0.3), or baseline MADRS (26.8±0.6 vs 25.0±0.8,
F¼ 3.0, p¼ 0.09) between responders and non-responders;
moreover, study center also did not influence treatment
response (p¼ 0.3).
We compared the baseline mRNA levels of each gene in
patients who did not respond to treatment vs patients who
did (Table 2). Only three genes were differentially
expressed: specifically, non-responders had higher mRNA
levels of the three pro-inflammatory cytokines, IL-1b (þ 33%,
F¼ 55.9, po0.0001), MIF (þ 48%, F¼ 14.6, po0.0001), and
TNF-a (þ 39%, F¼ 39.4, po0.0001). Moreover, for MIF
levels we observed a significant drug response interaction
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(F¼ 4.4, p¼ 0.04): this was due to the difference between
non-responders and responders being larger for non-
responders to nortriptyline (þ 56%, F¼ 73.2, po0.0001)
than for those non-responders to escitalopram (þ 39%,
F¼ 36.9, po0.0001). There was no drug response inter-
action for any of the other genes.
We further examined the relative contributions of the
three cytokines in predicting treatment response measured
as changes in the MADRS score between week 0 and week
12 (DMADRS), both in the overall sample and separately
based on the drug used. As expected, the expression
levels of IL-1b, MIF, and TNF-a at baseline were all strongly
and negatively correlated with the treatment outcome,
both in the entire group (IL-1b, r¼  0.56; MIF, r¼  0.62;
and TNF-a, r¼  0.44; all po0.0001), and also separately
in the two samples based on the drug used (for
Table 1 Expression Levels of Genes Belonging to GR Functionality (FKBP-4, FKBP-5, and GR), Inflammation (IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8,
IL-10, TNF-a, and MIF), and Neuroplasticity (BDNF, p11, and VGF) in Controls and Depressed Patients with Statistics (p and F values and
Percentage Changes)
Gene Controls (mean±SEM) Patients (mean±SEM) F value p-Value Percentage change (%)
FKBP-4 0.99±0.01 0.98±0.01 0.2 0.70  1
FKBP-5 0.99±0.02 1.26±0.02 69.4 o0.0001 þ 27
GR 1.03±0.02 0.85±0.01 63.2 o0.0001  18
IL-1a 0.96±0.04 1.00±0.02 0.9 0.3 þ 4
IL-1b 1.03±0.03 1.51±0.03 117.9 o0.0001 þ 48
IL-4 0.99±0.02 0.90±0.02 5.6 0.02  9
IL-6 1.08±0.02 1.32±0.01 86.3 o0.0001 þ 24
IL-7 1.03±0.05 0.99±0.02 0.9 0.36  4
IL-8 1.00±0.04 1.01±0.01 0.2 0.68 þ 1
IL-10 1.00±0.02 1.02±0.01 1.1 0.31 þ 2
TNF-a 0.97±0.04 1.55±0.04 87.7 o0.0001 þ 58
MIF 0.98±0.04 1.30±0.03 34.8 o0.0001 þ 32
BDNF 0.95±0.04 0.71±0.01 46.5 o0.0001  24
p11 1.01±0.02 0.85±0.03 12.1 0.001  16
VGF 1.01±0.04 0.65±0.04 37.3 o0.0001  36
Table 2 Expression Levels of Genes Belonging to GR Functionality (FKBP-4, FKBP-5, and GR), Inflammation (IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8,
IL-10, TNF-a, and MIF), and Neuroplasticity (BDNF, p11, and VGF) in Non-Responder and Responder Patients
Gene Non-responder (n¼23) Responder (n¼ 51) F value p-Value Drug response interaction
F value p-Value
FKBP-4 1.00±0.02 0.99±0.02 0.2 0.7 0.2 0.7
FKBP-5 1.31±0.02 1.23±0.03 3.9 0.05 0.8 0.4
GRT0 0.83±0.02 0.86±0.02 0.8 0.38 0.6 0.4
IL-1a 0.97±0.04 1.02±0.03 0.9 0.33 0.2 0.7
IL-1b 1.74±0.05 1.41±0.02 55.9 o0.0001 0.03 0.8
IL-4 0.88±0.04 0.91±0.03 0.6 0.44 0.1 0.7
IL-6 1.35±0.02 1.30±0.02 2.8 0.10 1.8 0.2
IL-7 0.98±0.04 1.00±0.02 0.6 0.45 0.04 0.8
IL-8 1.00±0.02 1.01±0.02 0.02 0.89 3.6 0.06
IL-10 1.00±0.02 1.03±0.02 0.7 0.40 2.4 0.1
TNF-a 1.82±0.07 1.43±0.03 39.4 o0.0001 0.02 0.9
MIF 1.63±0.04 1.15±0.02 144.7 o0.0001 4.4 0.04
BDNF 0.68±0.02 0.72±0.02 1.6 0.2 0.3 0.6
p11 0.83±0.06 0.85±0.04 0.1 0.7 0.002 0.9
VGF 0.64±0.07 0.65±0.04 0.05 0.8 0.7 0.4
Statistics (F and p values) are presented for both main effects and for the drug response interaction (26 responders to escitalopram, 12 non-esponders to
escitalopram, 25 responders to nortryptline, and 11 non-responders to nortryptline).
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escitalopram: IL-1b, r¼  0.54, p¼ 0.001; MIF, r¼  0.73,
po0.0001; and TNF-a, r¼  0.39, p¼ 0.016; and for
nortriptyline, IL-1b, r¼  0.65 po0.0001; MIF, r¼  0.56
po0.0001; and TNF-a, r¼  0.68, po0.0001). We then run
a linear regression model to identify the relative contribu-
tions of the three cytokines to the prediction of response. As
shown in Table 3, the best predictive model was obtained
when the three cytokines were all included in the model,
both in the overall samples (46% of the variance) and
separately in the escitalopram-treated group (53% of the
variance) and in nortriptyline-treated group (48% of the
variance).
Change in Biomarkers and Relationship with Treatment
Response (‘Targets’)
To investigate the effect of 8 weeks of antidepressant treat-
ment with escitalopram or nortriptyline on gene expression
(and its relationship with treatment response), we compared
the change in mRNA levels of each gene between baseline
(T0) and week 8 (T8). These data are presented in Table 4.
Three genes were regulated by antidepressant treatment
but in responders only, and regardless of the antidepressant
used, as shown by significant response time interactions
but no drug time interactions. Specifically, antidepressant
treatment significantly reduced FKBP5 levels only in
patients who responded to the treatment ( 11%, F¼ 16.4,
po0.0001), whereas no effect was observed in non-res-
ponders ( 2%, F¼ 0.6, p¼ 0.45; response time interaction,
F¼ 4.4, p¼ 0.04; drug timeinteraction, F¼ 0.05, p¼ 0.8).
Moreover, antidepressant treatment significantly increased
VGF expression only in responders (þ 20%, F¼ 15.4,
po0.0001) but not in non-responders ( 3%, F¼ 0.002,
p¼ 0.97; response time interaction, F¼ 4.4, p¼ 0.039;
drug timeinteraction, F¼ 0.03, p¼ 0.8). Finally, antide-
pressant treatment increased BDNF expression more in the
responders (þ 48%, F¼ 126.4, po0.0001) than in the non-
responders (þ 21%, F¼ 49.4, po0.0001; response time
interaction, F¼ 17.8, po0.0001; drug time interaction,
F¼ 3.6, p¼ 0.062).
IL-6 was regulated by antidepressant treatment but in a
drug- and response-specific way, that is, in the presence of
both response time (F¼ 10.0, p¼ 0.002) and drug time
(F¼ 4.4, p¼ 0.039) interactions. Namely, IL-6 levels
decreased significantly in responders ( 9%, F¼ 20.3,
po0.0001), and this was present for both responders to
escitalopram ( 12%, F¼ 14.0, p¼ 0.001) and to nortripty-
line ( 6%, 0.2, F¼ 6.6, p¼ 0.02). In non-responders there
was no overall effect (þ 1%, F¼ 0.4, p¼ 0.5) but, when the
two drugs were analyzed separately, IL-6 did not change in
the non-responders to escitalopram ( 2%, F¼ 0.5, p¼ 0.5)
and increased in the non-responders to nortriptyline
(þ 7%, F¼ 5.8, p¼ 0.037).
Finally, four genes were regulated by antidepressant
treatment, irrespective of the antidepressant used or of
treatment response, as shown by a main effect of time in the
absence of any response time or drug timeinteractions.
Specifically, antidepressant treatment significantly reduced
the expression levels of IL-1b ( 6%, F¼ 7.9, p¼ 0.006) and
MIF ( 24%, F¼ 16.4, po0.0001), and increased GR mRNA
levels (þ 5%, F¼ 7.3, p¼ 0.009) and p11 levels (þ 8%,
F¼ 8.4, p¼ 0.005).
DISCUSSION
To provide evidence supporting a personalized-medicine
approach to the treatment of depression, we have assessed
the blood mRNA expression of 15 candidate genes across
three biological systems implicated in the pathogenesis of
depression and in the action of antidepressants: GR
complex, inflammation, and neuroplasticity. We have used
a well-characterized group of drug-free depressed patients
who entered a randomized trial with two different anti-
depressants, and we have assessed genes that differentiate
patients from controls, predict future antidepressants response,
or change in association with response. The main finding is
a dissociation between genes that predict treatment response
(‘predictors’) and genes that change longitudinally in patients
who respond (‘targets’). Specifically, among the 15 genes,
only higher levels of the three inflammation-related genes,
IL-1b, MIF, and TNF-a, predict lack of response to
antidepressants, and successful antidepressant response is
not associated with a reduction in the levels of these genes.
In contrast, successful antidepressant response is associated
with a reduction in the levels of the inflammation-related
gene, IL-6, and of the GR-associated gene, FKBP-5; and with
Table 3 Adjusted R2 Values and Significance of Linear Regression Model to Assess the Contribution of TNF-a, MIF, and IL-1b, Alone or in
Combination, in Predicting the Treatment Response in the Whole Sample, in the Escitalopram-Treated Group and in the Nortriptyline-
Treated Group
Whole sample (n¼74) Escitalopram-treated group (n¼38) Nortriptyline-treated group (n¼36)
Effects of each single cytokine as predictor of treatment response
TNF-a Adjusted R2¼ 0.19, po0.0001 Adjusted R2¼ 0.13, p¼ 0.016 Adjusted R2¼ 0.45, po0.0001
MIF Adjusted R2¼ 0.37, po0.0001 Adjusted R2¼ 0.51, po0.0001 Adjusted R2¼ 0.29, po0.0001
IL-1b Adjusted R2¼ 0.31, po0.0001 Adjusted R2¼ 0.27, p¼ 0.001 Adjusted R2¼ 0.41, po0.0001
Combined effects of cytokines as predictor of treatment response
TNF-a Adjusted R2¼ 0.19, po0.0001 Adjusted R2¼ 0.13, p¼ 0.016 Adjusted R2¼ 0.45, po0.0001
TNF-aþMIF Adjusted R2¼ 0.40, po0.0001 Adjusted R2¼ 0.50, po0.0001 Adjusted R2¼ 0.47, po0.0001
TNF-aþMIFþ IL-1b Adjusted R2¼ 0.46, po0.0001 Adjusted R2¼ 0.53, po0.0001 Adjusted R2¼ 0.48, po0.0001
Gene expression profile in the GENDEP study
A Cattaneo et al
381
Neuropsychopharmacology
an increase in the neuroplasticity-associated genes, VGF
and BDNF—that is, in genes that are not associated with the
baseline prediction of treatment response.
The baseline levels of TNF-a, IL1-b, and MIF, together
predict the treatment outcome for both antidepressants, with
clinically significant effect sizes of around 50% of the
variance (Uher et al, 2012). Moreover, although each single
cytokine strongly correlates with the treatment response, the
best predictive model is present when we include all three
cytokines in the linear regression, suggesting that each
cytokine taps also in non-shared molecular mechanisms. For
example, IL1-b and TNF-a, but not MIF, activate the
indoleamine 2,3-dioxygenase pathway (Capuron et al,
2003; O’Connor et al, 2009), which is responsible for the
catabolism of tryptophan to kynurenine, and results in the
production of the neurotoxic and depressogenic metabolites,
3-hydroxykynurenine and quinolinic acid (Raison et al,
2010). Indeed, we have recently shown that this pathway is
activated by IL-1b also in human neurons (Zunszain et al,
2012). In contrast, MIF, but not IL-1b and TNF-a, is released
in response to glucocorticoids, and, when secreted, it
renders immune cells less sensitive to the anti-inflammatory
effects of glucocorticoids (Kitaichi et al, 2000).
It is also of note that antidepressant treatment in our
study reduces the levels of IL1-b andMIF, but this reduction
is not associated with treatment response. In contrast, levels
of TNF-a, which are elevated in non-responders, are not
modified by antidepressant treatment; and levels of IL-6
decrease following antidepressants, but in responders only.
Of note, this last finding is remarkably consistent with the
previous paper by Yoshimura et al (2009), who also found
that IL-6 plasma levels after 8 weeks of antidepressant
treatment were reduced in responders only. Although these
data confirm previous evidence showing that antidepres-
sants have anti-inflammatory properties (Hiles et al, 2012;
Taler et al, 2007), here we also demonstrate that the changes
in inflammation associated with antidepressant response
are not reflected by all cytokines at the same time. This is
perhaps not surprising, because the action of a single
cytokine is regulated within a complex network, where
multiple pro-inflammatory cytokines maybe involved in the
antidepressant response, and a reduction in inflammation
may be signaled by an increase in the expression of negative
regulators of cytokine action as well as by a reduction in
cytokines level. It is also possible that a simple reduction in
the levels of some inflammatory biomarkers, such as IL1-b
and MIF, is not sufficient for reversing the biological
changes underlying the depressive symptoms, because
potentially downstream effectors pathways, such as MAPK
and nuclear factor kappa B, remain abnormal (Haroon et al,
2012). At the opposite end, persistently high levels of other
inflammatory cytokines, such as TNF-a, may be a marker of
specific forms of depression that are less responsive to
antidepressant treatment, eg, depressed patients with a
history of childhood trauma tend to have higher inflam-
matory biomarkers (Danese et al, 2008) and to be less
responsive to pharmacological intervention (Nanni et al,
2012; Nemeroff et al, 2003); in this case, the increased
cytokine levels may be an underlying ‘trait feature’ conferring
treatment resistance, and may not be modifiable by
antidepressants.
The expression of four genes changes only in patients
who respond to treatment, but not in those who do not
respond. These genes are across the three biological systems
investigated: the GR-associated gene, FKBP-5; the pro-
inflammatory cytokine, IL-6 (as mentioned above); and the
neuroplasticity associated genes, VGF and BDNF. The
association between reduction in FKBP-5 and response to
Table 4 Expression Levels of Genes Belonging to GR Functionality (FKBP-4, FKBP-5, and GR), Inflammation (IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8,
IL-10, TNF-a, and MIF), and Neuroplasticity (BDNF, p11, and VGF) in Depressed Patients before (Patients T0) and after 8 Weeks of
Antidepressant Treatment (Patients T8)
Gene Patients T0 Patients T8 Time effect Time response interaction Timedrug interaction
F value p-Value F value p-Value F value p-Value
FKBP-4 0.99±0.01 0.98±0.01 0.9 0.4 0.04 0.9 0.4 0.6
FKBP-5 1.26±0.02 1.17±0.02 8.5 0.005 4.4 0.04 0.05 0.8
GR 0.85±0.01 0.89±0.01 7.3 0.009 0.2 0.7 1.1 0.3
IL-1a 1.00±0.02 1.02±0.02 1.6 0.2 2.2 0.1 0.9 0.4
IL-1b 1.51±0.03 1.45±0.03 7.9 0.006 1.7 0.20 1.7 0.2
IL-4 0.90±0.02 0.96±0.03 3.4 0.07 0.02 0.9 0.1 0.7
IL-6 1.32±0.01 1.26±0.02 4.7 0.03 10.02 0.002 4.4 0.04
IL-7 0.99±0.02 1.00±0.03 0.3 0.6 1.8 0.2 o0.01 0.9
IL-8 1.01±0.01 1.02±0.01 0.06 0.8 0.9 0.4 0.1 0.7
IL-10 1.02±0.01 1.02±0.02 0.09 0.8 0.5 0.5 o0.01 1.0
MIF 1.30±0.03 1.06±0.06 16.4 o0.0001 0.06 0.8 1.1 0.3
TNF-a 1.55±0.04 1.52±0.04 0.3 0.6 0.03 0.9 0.2 0.7
BDNF 0.71±0.01 1.10±0.03 120.5 o0.0001 17.8 o0.0001 3.6 0.06
P11 0.85±0.03 0.93±0.02 8.4 0.005 0.3 0.6 0.05 0.8
VGF 0.65±0.04 0.79±0.04 4.8 0.033 4.4 0.04 0.03 0.9
Statistics (F and p values) are presented for the time effect as well as the time response and time drug interactions. The numbers of patients for each group were:
26 responders to escitalopram, 12 non-responders to escitalopram, 25 responders to nortryptline, and 11 non responders to nortryptline).
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antidepressants has never, to our knowledge, been de-
scribed before; but previous studies have demonstrated that
polymorphisms in the gene encoding this co-chaperone are
associated with antidepressant response (Binder, 2009;
Horstmann et al, 2010; Lekman et al, 2008). Moreover,
Menke et al (2012) have recently shown that the pattern of
RNA levels of GR-stimulated genes, including FKBP-5,
discriminate between patients and controls (Menke et al,
2012). Taken together, our data (see also the changes in GR
discussed below) suggest that depression is characterized by
the coexistence of higher FKBP-5 and lower GR, leading to
GR resistance, and that successful antidepressant treatment
requires normalization of GR function. Finally, treatment
response was associated with an increase in BDNF and VGF.
The evidence for a role of BDNF in depression is abundant
(Bocchio-Chiavetto et al, 2010). It is also of note that the
recent study from Rojas et al (2011), describing patients
who responded to an open-labeled treatment with venlafax-
ine, also showed an increase in serum BDNF by week 3 of
treatment. Also of interest is a large cross-sectional study
(Molendjik et al, 2011), again showing that depressed
patients had lower levels of serum BDNF, whereas remitted
patients (a different group) had normal levels. There are less
data on the role of VGF in depression, but previous studies
have shown that VGF modulates hippocampal function and
behavior through an effect that is BDNF-dependent and that
it is involved both in the pathogenesis of depression and in
the effects of antidepressants (Cattaneo et al, 2010a, b;
Thakker-Varia et al, 2010).
We also find that GR and p11 levels are lower in depressed
patients compared with controls, and that their levels
increase after antidepressants, but not in relationship with
treatment response. Both lower levels of GR and lower levels
of p11, which is considered a GR-target gene via two specific
glucocorticoid response elements in its promoter (Zhang
et al, 2008), have been described before in depressed
patients (Anacker et al, 2011; Snyder et al, 2011). To our
knowledge, this is the first report describing prospective
changes in p11 levels; and only one previous study has
assessed GR expression prospectively using radioactive
dexamethasone binding in peripheral blood mononuclear
cells, and, again, found a reduction of GR density in depressed
patients (compared with controls) and an increase after
antidepressant treatment (Calfa et al, 2003). Of note, we
have consistently shown that antidepressants regulate the
function and the expression of the GR (Jurena et al, 2010;
Pariante et al, 1997, 2003, 2004, 2012; Pariante and Miller,
2001). Moreover, a recent study in rats has shown that
escitalopram increases brain p11 levels concomitantly to a
decrease in the p11 promoter methylation (Melas et al,
2011). Indeed, our own research in human neuronal stem
cells has recently shown that antidepressants directly increase
the function of the GR and, via a GR-dependent mechanism,
the expression of p11: an action that is required for the effects
of antidepressants on neurogenesis (Anacker et al, 2011).
It is interesting to note that, except for IL-6, we have
found that all the examined genes are modulated in the
same way by both drugs, even if escitalopram and nortry-
ptiline have different modes of action. We believe this is due
to the fact that we have examined genes that belong to
pathways that are in common to both drugs (Uher et al,
2009), rather than genes that are modulated differently by
the two drugs, that is, belonging to the serotonergic and the
noradrenergic pathways, respectively. This is also in line
with the results of our previous genetic study in the same
GENDEP sample (Uher et al, 2009).
The main limitation of this study is that our finding
cannot yet be used to change clinical practice. Notwith-
standing the strengths of the randomized, longitudinal design,
these findings need to be replicated in an independent sample.
Moreover, the predictive biomarkers that we have identified
are not specific to one or the other of the antidepressants,
and as such could not be used to guide the choice of anti-
depressants but rather to identify patients that potentially
may be helped by early access to adjuvant therapies.
Moreover, it is possible that these gene expression changes
are not causally involved in the treatment response, and
indeed we have not investigated potential biological mechan-
isms that are changed by antidepressants and may underlie
the gene expression changes that we have described, such as
changes in immune cells composition or in cortisol levels.
In conclusion, our findings identify for the first time that
the baseline levels of MIF, IL1-b, and TNF-a are ‘predictors’
of antidepressant treatment response. Moreover, we show
that an enhancement of GR function and an improvement
in neuroplasticity are needed to observe a response to
antidepressant therapies, suggesting that future antidepres-
sant strategies should specifically target these pathways.
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